Currently, there are 55.90M common shares owned by the public and among those 37.37M shares have been available to trade.
The company’s stock has a 5-day price change of 258.17% and 222.33% over the past three months. SPRO shares are trading 142.72% year to date (YTD), with the 12-month market performance up to 73.61% higher. It has a 12-month low price of $0.51 and touched a high of $2.48 over the same period. SPRO has an average intraday trading volume of 3.21 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 178.03%, 217.72%, and 144.56% respectively.
Institutional ownership of Spero Therapeutics Inc (NASDAQ: SPRO) shares accounts for 20.66% of the company’s 55.90M shares outstanding.
It has a market capitalization of $139.78M and a beta (3y monthly) value of 1.10. The earnings-per-share (ttm) stands at -$1.28. Price movements for the stock have been influenced by the stock’s volatility, which stands at 62.12% over the week and 28.21% over the month.
Analysts forecast that Spero Therapeutics Inc (SPRO) will achieve an EPS of -0.32 for the current quarter, -0.25 for the next quarter and 0 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.32 while analysts give the company a high EPS estimate of -0.32. Comparatively, EPS for the current quarter was -0.33 a year ago. Earnings per share for the fiscal year are expected to increase by 9.45%, and -41.74% over the next financial year. EPS should shrink at an annualized rate of 7.97% over the next five years, compared to 17.67% over the past 5-year period.
Looking at the support for the SPRO, a number of firms have released research notes about the stock. Evercore ISI stated their In-line rating for the stock in a research note on December 20, 2024, with the firm’s price target at $5. Evercore ISI coverage for the Spero Therapeutics Inc (SPRO) stock in a research note released on September 23, 2022 offered a Outperform rating with a price target of $8. Oppenheimer was of a view on October 01, 2021 that the stock is Perform, while H.C. Wainwright gave the stock Buy rating on January 22, 2021, issuing a price target of $33- $40. Berenberg on their part issued Buy rating on December 16, 2020.
